Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) traded down 5% during mid-day trading on Friday . The stock traded as low as $24.34 and last traded at $24.34. 150,997 shares traded hands during trading, a decline of 67% from the average session volume of 455,413 shares. The stock had previously closed at $25.63.
Analyst Ratings Changes
Several research analysts have recently commented on SYRE shares. BTIG Research lifted their target price on Spyre Therapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Wells Fargo & Company lifted their price objective on shares of Spyre Therapeutics from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, May 13th. Robert W. Baird started coverage on shares of Spyre Therapeutics in a report on Thursday, May 2nd. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Stifel Nicolaus lifted their price target on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $43.17.
Check Out Our Latest Research Report on SYRE
Spyre Therapeutics Price Performance
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its earnings results on Monday, May 13th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities analysts forecast that Spyre Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Read More
- Five stocks we like better than Spyre Therapeutics
- Stock Splits, Do They Really Impact Investors?
- Sarepta Therapeutics Stock Soars on FDA Approval
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- What is an Earnings Surprise?
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.